Примери за използване на Intravenous formulation на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Caution is recommended with Herceptin subcutaneous formulation as severe pulmonary events have been reported with the use of the intravenous formulation in the post-marketing setting(see section 4.8).
Препоръчва се повишено внимание с Herceptin As with the intravenous formulation, MabThera subcutaneous formulation should be administered in an environment where full resuscitation facilities are immediately available
Както при интравенозната лекарствена форма, MabThera When switching from the maintenance therapy of infliximab intravenous formulation to the subcutaneous formulation of Remsima,
Когато се преминава от поддържащата терапия с интравенозна лекарствена форма на инфликсимаб към подкожна they should continue the subsequent cycles with MabThera intravenous formulation until a full intravenous dose is successfully administered.
те трябва да продължат следващите цикли с интравенозна лекарствена форма на MabThera, докато успешно се приложи пълна Signs and symptoms suggestive of an infusion-related reaction were reported in more than 50% of patients in clinical trials involving MabThera intravenous formulation, and were predominantly seen during the first infusion, usually in the first one to two hours.
Признаци и симптоми, предполагащи реакция, свързана с инфузията, се съобщават при над 50% от пациентите при клиничните изпитвания, включващи MabThera интравенозна лекарствена форма, и са наблюдавани предимно по време на първата инфузия, обикновено през първите един до два часа.close to the end of the infusion for the intravenous formulation.
близо до края на инфузията при интравенозната лекарствена форма.The mean AUC0-21 days following the Cycle 7 dose was approximately 10% higher with the Herceptin subcutaneous formulation as compared to the Herceptin intravenous formulation, with mean AUC values of 2268 µg/mL•day and 2056 µg/mL•day.
Средната AUC0-21 days след дозата в Цикъл 7 е приблизително 10% по-висока в рамото Study BO22227 was designed to demonstrate non-inferiority of treatment with Herceptin subcutaneous formulation versus Herceptin intravenous formulation based on co-primary PK and efficacy endpoints(trastuzumab Ctrough at pre-dose Cycle 8,
Клиничното проучване BO22227 е планирано да демонстрира не по-ниската ефикасност на лечението с Herceptin CVP versus MabThera intravenous formulation in combination with CHOP or CVP.
спрямо MabThera лекарствена форма за интравенозно приложение в комбинация с CHOP или CVP.the CHMP concluded that an intravenous formulation of nicardipine is a useful treatment for high blood pressure in specific settings
СНМР заключава, че интравенозната форма на никардипин е полезна за лечение на високо кръвно налягане в специфични болнични условияpatients with relapsed low-grade NHL who received the MabThera intravenous formulation as monotherapy when compared to healthy untreated controls had a lower rate of response to vaccination with tetanus recall antigen(16% vs. 81%) and Keyhole Limpet Haemocyanin(KLH) neoantigen(4% vs. 69% when assessed for> 2-fold increase in antibody titer).
MabThera intravenous formulation 375 mg/m2 body surface area administered on day 0 of the first cycle of treatment followed by MabThera subcutaneous formulation injected at a fixed dose of 1600 mg per cycle,
MabThera лекарствена форма за интравенозно приложение 375 mg/m телесна повърхност, приложена на ден 0 от първия цикъл на лечение, последвана от MabThera The pivotal trial BO22227 was designed to demonstrate non-inferiority of treatment with Herceptin subcutaneous formulation versus treatment with Herceptin intravenous formulation based on coprimary PK and efficacy endpoints(trastuzumab Ctrough at pre-dose Cycle 8,
Основното клинично изпитване BO22227 е планирано да докаже не по-лоша ефикасност на лечението с Herceptin asymptomatic cardiac events was observed when Herceptin( intravenous formulation) was administered after anthracyclinecontaining chemotherapy compared to administration with a non-anthracycline regimen of docetaxel and carboplatin and was more marked when Herceptin( intravenous formulation) was administered concurrently with taxanes than when administered sequentially to taxanes.
наблюдавано увеличение на честотата на симптомните и асимптомните сърдечни събития, когато Herceptin лекарствена форма за интравенозно приложение е прилаган след химиотерапия, съдържаща антрациклини, в сравнение с Intravenous formulation.
Hypotension, particularly with intravenous formulation.
Хипотония, особено при интравенозните форми.Uncommon Bradycardia, particularly with intravenous formulation.
Нечести Брадикардия, особено при интравенозни форми.Tabulated list of adverse reactions with the intravenous formulation.
Табличен списък на нежеланите реакции при интравенозно приложение.As a consequence, the intravenous formulation was withdrawn worldwide.
Поради това интравенозната лекарствена форма е изтеглена навсякъде по света.For instructions on reconstitution of Ontruzant intravenous formulation before administration, see section 6.6.
